EU and IACR conference data will blow away analyst.
dotsciencedailydotcom/releases/2014/03/140321164848dot adddddd htm here
I think CEO was in the EU last time I spoke with him. The conference call isn't an earnings call as you'd think. Rather, they are in the process of rolling out assays. And clinical data will be the driver of this ship, then reimbursement and finally, adopting of platform by docs. Continue upside in PPS can be anticipated as molecular testing gains traction in diagnostics/monitoring oncogene mutations.
Fill in dot with a real dot ...........................
Absent uncrontrolled expression and severe immune response-Gene therapy stocks were what the internet was to technology. This could ride to $1,000 and perhaps become the most expensive drug stock ever.
Could it be that product demand is high and managing the store is needed or has CR stuck a band-aid on lack luster results. Vote if its history in the making or no annual profits for shareholders since 2005?